We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+14.22%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$195M
AUM Growth
+$55.6M
Cap. Flow
+$47.8M
Cap. Flow %
24.49%
Top 10 Hldgs %
95.21%
Holding
19
New
4
Increased
2
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$59.9M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$3.77M
3
OBSV
ObsEva SA Ordinary Shares
OBSV
+$2.46M
4
OTIC
Otonomy, Inc.
OTIC
+$1.32M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$1.08M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$10.4M
2
DERM
Dermira, Inc.
DERM
+$3.6M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.21M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$1.32M
5
DVAX
Dynavax Technologies
DVAX
+$1.01M

Sector Composition

Rank Sector Weight
1 Healthcare 98.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
1
iRhythm Holdings
IRTC
$3.59B
$65.5M 33.55%
+1,741,589
New +$59.9M
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$30.9M 15.84%
241,383
-98,488
-29% -$10.4M
PDSB icon
3
PDS Biotechnology
PDSB
$38.4M
$21.4M 10.94%
117,243
– –
WVE icon
4
Wave Life Sciences
WVE
$1.12B
$18.1M 9.27%
658,259
– –
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$17.9M 9.15%
1,152,497
-225,000
-16% -$3.21M
CRSP icon
6
CRISPR Therapeutics
CRSP
$4.61B
$12.8M 6.54%
586,475
– –
SAGE
7
DELISTED
Sage Therapeutics
SAGE
$7.04M 3.61%
99,123
-15,000
-13% -$879K
ALDR
8
DELISTED
Alder Biopharmaceuticals
ALDR
$4.75M 2.43%
228,428
– –
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.97M 2.03%
+64,815
New +$3.77M
DMTX
10
DELISTED
Dimension Therapeutics, Inc
DMTX
$3.6M 1.85%
2,059,283
– –
AVEO
11
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.41M 1.24%
409,067
+150,000
+58% +$1.08M
DERM
12
DELISTED
Dermira, Inc.
DERM
$2.25M 1.16%
66,109
-111,735
-63% -$3.6M
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.08M 1.07%
+200,000
New +$2.46M
OTIC
14
DELISTED
Otonomy, Inc.
OTIC
$1.11M 0.57%
+90,950
New +$1.32M
EVAR
15
DELISTED
Lombard Medical, Inc.
EVAR
$837K 0.43%
1,072,634
– –
TRIL
16
DELISTED
Trillium Therapeutics Inc.
TRIL
$641K 0.33%
104,159
+7,400
+8% +$43.4K
DVAX
17
DELISTED
Dynavax Technologies
DVAX
– –
-256,381
Closed -$1.01M
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$353M
– –
-15,575
Closed -$380K
VTGN icon
19
VistaGen Therapeutics
VTGN
$9.14M
– –
-11,765
Closed -$1.32M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q1 2017 Portfolio in Review

As of Q1 2017, New Leaf Venture Partners held 19 positions worth $195M, up 40% from $140M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

New Leaf Venture Partners deployed $47.8M of net new capital in Q1 2017, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was iRhythm Holdings: 1,741,589 shares worth $65.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $10.4M trimmed.

  • New Leaf Venture Partners's largest Q1 2017 buy was iRhythm Holdings: 1,741,589 shares worth $65.5M.
  • New Leaf Venture Partners added most to AVEO Pharmaceuticals, Inc. in Q1 2017, an estimated $1.08M increase.
  • New Leaf Venture Partners's biggest Q1 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $10.4M.
  • New Leaf Venture Partners fully exited VistaGen Therapeutics in Q1 2017, selling an estimated $1.32M.
  • New Leaf Venture Partners's ten largest holdings make up 95% of its $195M portfolio in Q1 2017.
  • New Leaf Venture Partners opened 4 new positions and closed 3 in Q1 2017.
  • New Leaf Venture Partners's portfolio value rose 40% quarter-over-quarter to $195M.

Based on New Leaf Venture Partners's 13F filing for Q1 2017, filed 15 May 2017.